We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Johnson Matthey, Domainex Collaborate

Rectangle Image
News

Johnson Matthey, Domainex Collaborate

Read time:
 

Johnson Matthey and Domainex Ltd. have announced a collaboration to provide integrated small molecule pharmaceutical discovery and development services. The focus will be on providing academic institutes, biotechnology and pharmaceutical companies across the UK and beyond with effective, simplified, rapid and reduced risk target-to-lead identification, optimisation, safety/toxicology, pre-clinical and clinical API supply services. 

Domainex is a leading provider of small molecule drug discovery services that complement the pre-clinical to commercial range of services provided by Johnson Matthey Fine Chemicals’ Custom Pharma Solutions offering in Europe. Through an integrated offering co-located in the Cambridge region, customers will be able to access Domainex’s target-to-lead identification and optimisation capabilities, and will then be able to transfer their projects directly to Johnson Matthey, utilising its Pharmorphix solid state services for effective salt form and polymorph identification through to process development, scale-up and non-GMP toxicology manufacture. With all activities co-located in the Cambridge area, discovery and development time and risk can be greatly minimised.

“Johnson Matthey and Domainex have together recognised there is customer demand for simplified and effective drug discovery and development services.

With our combined expertise and facilities based in Cambridge, UK, we are now able to offer customers significant value through this joint service offering,” said Antoine Bordet, European Managing Director at Johnson Matthey Fine Chemicals. 

“The transition from drug discovery and candidate nomination into polymorph screening, pre-clinical toxicology and Phase I clinical development is a critical phase in the drug development process,” added Tom Mander, COO of Domainex. “We’re bringing together the necessary complementary people, skills and facilities with Johnson Matthey so that together we can offer an integrated and simplified solution spanning pharmaceutical discovery through to clinical development.” 

Advertisement